AstraZeneca trial failures dent investor confidence

3 min read

AstraZeneca faces investor scrutiny after an unexpected Phase III failure of Wainua in a heart disease trial erased roughly $20 billion of market value and contributed to a 10% share decline this year. The company's long-term CEO Pascal Soriot has overseen strong share gains over 14 years, supported by a diverse marketed portfolio and clinical successes, but attention now shifts to two late-stage oncology readouts, SERENA-4 and AVANZAR, due this year; further negative results could intensify questions about trial design, pipeline selection and growth plans.

Wainua Phase III failure erased about $20 billion in market value